Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015.

Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, Yeboa DN.

Anticancer Res. 2019 Jan;39(1):253-259. doi: 10.21873/anticanres.13105.

PMID:
30591466
2.

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.

Foss FM, Parker TL, Girardi M, Li A.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e445-e447. doi: 10.1016/j.clml.2018.06.020. Epub 2018 Jun 27. No abstract available.

PMID:
30181105
3.

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I.

Am J Hematol. 2018 Nov;93(11):1318-1326. doi: 10.1002/ajh.25243. Epub 2018 Oct 20.

PMID:
30094870
4.

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.

Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M.

Oncotarget. 2018 Jun 26;9(49):29193-29207. doi: 10.18632/oncotarget.25670. eCollection 2018 Jun 26.

5.

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.

Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH; T cell Project Network.

Br J Haematol. 2018 Jun;181(6):760-769. doi: 10.1111/bjh.15258. Epub 2018 Apr 19.

6.

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.

Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M; International T-cell Project Network.

Haematologica. 2018 Jul;103(7):1191-1197. doi: 10.3324/haematol.2017.186577. Epub 2018 Mar 29.

7.

A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Foss FM, Parker T.

Oncologist. 2018 Apr;23(4):397-e30. doi: 10.1634/theoncologist.2017-0658. Epub 2018 Feb 7.

8.

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM.

Blood. 2018 Feb 22;131(8):888-898. doi: 10.1182/blood-2017-08-802470. Epub 2017 Dec 12.

PMID:
29233821
9.

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M.

Blood. 2017 Nov 9;130(19):2073-2083. doi: 10.1182/blood-2017-06-792150. Epub 2017 Oct 2.

10.

Neurolymphomatosis of the thoracic sympathetic chain.

Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM.

Neurology. 2017 Oct 31;89(18):1926-1927. doi: 10.1212/WNL.0000000000004600. Epub 2017 Sep 22. No abstract available.

11.

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.

Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):520-526.e2. doi: 10.1016/j.clml.2017.05.017. Epub 2017 Jun 24.

PMID:
28655598
12.

Mycosis Fungoides and Sezary Syndrome.

Foss FM, Girardi M.

Hematol Oncol Clin North Am. 2017 Apr;31(2):297-315. doi: 10.1016/j.hoc.2016.11.008. Review.

PMID:
28340880
13.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
14.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

15.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.

Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12. No abstract available.

16.

Genomic landscape of cutaneous T cell lymphoma.

Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP.

Nat Genet. 2015 Sep;47(9):1011-9. doi: 10.1038/ng.3356. Epub 2015 Jul 20.

17.

Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.

Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM.

Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015.123711. Epub 2015 Mar 20.

18.

A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis.

Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM.

Clin Case Rep. 2015 Jan;3(1):34-8. doi: 10.1002/ccr3.142. Epub 2014 Nov 17.

19.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH.

Blood. 2015 Mar 19;125(12):1883-9. doi: 10.1182/blood-2014-09-600924. Epub 2015 Jan 20.

20.

Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.

Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD.

J Am Acad Dermatol. 2013 Oct;69(4):537-43. doi: 10.1016/j.jaad.2013.04.063. Epub 2013 Jul 9.

PMID:
23849563
21.

Treatment strategies for peripheral T-cell lymphomas.

Foss FM.

Best Pract Res Clin Haematol. 2013 Mar;26(1):43-56. doi: 10.1016/j.beha.2013.04.005. Epub 2013 May 25. Review.

PMID:
23768640
22.

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V.

Leuk Lymphoma. 2013 Jul;54(7):1373-9. doi: 10.3109/10428194.2012.742521. Epub 2013 Jan 29.

PMID:
23278639
23.

T-cell lymphomas in South america and europe.

Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M.

Rev Bras Hematol Hemoter. 2012;34(1):42-7. doi: 10.5581/1516-8484.20120013.

24.

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.

Foss FM.

Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1141-52. doi: 10.1517/17425255.2011.595404. Epub 2011 Jul 5. Review.

PMID:
21726160
25.

Peripheral T-cell lymphoma.

Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K.

Blood. 2011 Jun 23;117(25):6756-67. doi: 10.1182/blood-2010-05-231548. Epub 2011 Apr 14. Review.

26.

Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.

Armitage JO, Hsi ED, Foss FM.

Clin Adv Hematol Oncol. 2010 Dec;8(12 Suppl 22):1-15. Review.

PMID:
21491667
27.

Molecular predictors of response in aggressive T-cell lymphomas.

Foss FM.

Cancer J. 2011 Mar-Apr;17(2):142-8. doi: 10.1097/PPO.0b013e31821828b7. Review.

PMID:
21427558
28.

Enhancing existing approaches to peripheral T-cell lymphoma.

Foss FM.

Semin Hematol. 2010 Apr;47 Suppl 1:S8-10. doi: 10.1053/j.seminhematol.2010.01.012. Review.

PMID:
20359584
29.

Current and emerging treatment strategies for cutaneous T-cell lymphoma.

Lansigan F, Foss FM.

Drugs. 2010 Feb 12;70(3):273-86. doi: 10.2165/11532190-000000000-00000. Review.

PMID:
20166766
30.

The importance of accurately characterizing lymphoproliferative disease.

Foss FM.

Oncology (Williston Park). 2009 Nov 30;23(13):1168, 1170. No abstract available.

31.

Alcohol consumption and non-Hodgkin lymphoma survival.

Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y.

J Cancer Surviv. 2010 Jun;4(2):101-9. doi: 10.1007/s11764-009-0111-4. Epub 2009 Dec 29.

32.

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y.

Am J Hematol. 2010 Jan;85(1):51-6. doi: 10.1002/ajh.21580.

33.

Cutaneous T-cell lymphoma.

Lansigan F, Choi J, Foss FM.

Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x. doi: 10.1016/j.hoc.2008.07.014. Review.

PMID:
18954747
34.

Mycosis fungoides: pathophysiology and emerging therapies.

Duvic M, Foss FM.

Semin Oncol. 2007 Dec;34(6 Suppl 5):S21-8. Review.

PMID:
18086343
35.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.

J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.

PMID:
17577020
36.
37.
38.
39.

Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.

Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB.

Bone Marrow Transplant. 2005 Jun;35(12):1187-93.

PMID:
15852025
40.

Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.

Foss FM.

Best Pract Res Clin Haematol. 2004 Dec;17(4):573-84. Review.

PMID:
15494295
41.

A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.

Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, Gorgun G, Relias V, Grodman H, Mahajan A, Foss FM.

Bone Marrow Transplant. 2004 May;33(9):881-9.

PMID:
14990986
42.

Novel agents for cutaneous T-cell lymphoma.

Kuzel TM, Junghans R, Foss FM.

Hematol Oncol Clin North Am. 2003 Dec;17(6):1459-66, x. Review.

PMID:
14710896
43.

Interleukin-2 receptor-directed therapies for cutaneous lymphomas.

Foss FM, Waldmann TA.

Hematol Oncol Clin North Am. 2003 Dec;17(6):1449-58. Review.

PMID:
14710895
44.

Peripheral T-cell lymphomas: diagnosis and management.

Dearden CE, Foss FM.

Hematol Oncol Clin North Am. 2003 Dec;17(6):1351-66. Review.

PMID:
14710889
45.

Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.

Chan GW, Foss FM, Klein AK, Sprague K, Miller KB.

Biol Blood Marrow Transplant. 2003 Dec;9(12):753-9.

46.

Extracorporeal photopheresis in the treatment of graft-vs-host disease.

Foss FM.

J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):13-7. No abstract available.

PMID:
12958702
48.

Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.

Chan GW, Gorgun G, Miller KB, Foss FM.

Biol Blood Marrow Transplant. 2003 Mar;9(3):170-6.

49.

Lymphoma of the skin.

Connors JM, Hsi ED, Foss FM.

Hematology Am Soc Hematol Educ Program. 2002:263-82. Review.

PMID:
12446427
50.

Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene.

Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM.

Leuk Res. 2002 Dec;26(12):1077-83.

PMID:
12443879

Supplemental Content

Support Center